Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Peptides Stories

2012-01-12 14:41:34

Brain cancer cells are particularly resistant to chemotherapy – toxins enter the cells, but before the toxins can kill, cancer cells quickly pump them back outside.  In fact, brain cancer cells are even better than healthy cells at cleaning themselves. This means that when hit with chemotherapy, healthy cells tend to die before brain cancer cells. Especially in the brain, killing healthy cells is bad. Researchers at the University of Colorado Cancer Center have discovered a way...

2012-01-04 08:00:00

PALO ALTO, Calif., Jan. 4, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate update at the 5th Annual OneMedForum Conference on Wednesday, January 11 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time) in San Francisco. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the presentation can be accessed for 30 days following the...

2011-12-12 13:28:32

Discovery of subcellular processing location and target signal of cyclotide kalata B1 Many plants produce compounds that serve as a defense against predators or pathogens. Some are also used by humans for a variety of beneficial purposes, such as in medicines. As recently as the early 1990s, a unique class of proteins previously unknown to science, the cyclotides, was discovered. First noted through African tribal use as a tea given to speed up delivery during childbirth, cyclotides have...

2011-12-06 23:15:40

Research presented at ASCB annual meeting Is obesity a ciliopathy, a disorder such as polycystic kidney disease (PKD), which is triggered by a defect in the microscopic hair-like cilia that protrude from virtually every cell of humans and other vertebrates? University of Alabama, Birmingham (UAB) researchers told the American Society for Cell Biology (ASCB) 2011 Annual Meeting in Denver on Dec. 6 that mutations in primary cilia may scramble signaling pathways in the hypothalamus, the...

2011-11-30 05:55:00

WESTLAKE VILLAGE, Calif., Nov. 30, 2011 /PRNewswire/ -- Envy Medical Inc., announced the launch of the Lumixyl Revitaleyes Brightening Eye Cream, the latest addition to the Lumixyl Topical Brightening System of products for an even skin tone and a brighter, healthier complexion. (Photo: <font size="2" face="Arial">http://photos.prnewswire.com/prnh/20111130/NY14300</font>) What makes Lumixyl Revitaleyes special? It is the first and only eye cream formulated with...

2011-11-21 00:30:00

SEATTLE, Nov. 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application directed to increasing the plasma half-life of therapeutic proteins and peptides by recombinantly conjugating them to a novel, non-immunogenic peptide repeat sequence. The patent and its related technology are exclusively licensed to Aequus Biopharma, Inc. (Aequus), a...

2011-11-14 14:02:00

BASKING RIDGE, N.J., Nov. 14, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announces one poster presentation and two oral presentations at the American Heart Association (AHA) Scientific Sessions meeting on November 14, 2011 during the 9:00 a.m. - 5:00 p.m. EST session. All three presentations highlight results from Regado's pipeline of antithrombotic agents for the treatment of...

2011-11-07 10:02:00

BASKING RIDGE, N.J., Nov. 7, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced the presentation of two posters highlighting positive substudy results of the Company's Phase 2b RADAR trial of REG1, Regado's proprietary anticoagulation system. The posters will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium meeting on November 8, 2011 from 8:00-10:00...

2011-10-31 22:59:00

BOULDER, Colo., Oct. 31, 2011 /PRNewswire/ -- Azantis launched today two innovative liposomal products: reduced glutathione and vitamin C. Both oral supplements are formulated in liposomal form to maximize absorption and to minimize side effects. Azantis, a leading phospholipid manufacturer, markets the liposomal products to resellers targeting the health care practitioner channel. The liposomal glutathione contains 500 mg reduced glutathione per recommended daily dose. These...

2011-10-18 16:37:00

BOULDER, Colo., Oct. 18, 2011 /PRNewswire/ -- SomaLogic, Inc., announced today that it has entered into a multi-year research agreement with Novartis to use its unique proprietary proteomics technology to accelerate Novartis' drug discovery and development efforts. "We are excited by this opportunity to work with Novartis' world-class researchers to help them define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics," said Larry Gold, CEO of...